KLRK1 and acute myeloid leukemia: Our findings highlight the complex dynamics of the immune microenvironment in AML and emphasize how immune checkpoint molecules, especially TIGIT, contribute to immune exhaustion, while NKG2D appears to support favorable clinical outcomes through its expression on γδ T cells.